NTS-WBRT in Brain Metastases

{ "NTS-WBRT and Memantine for Brain Metastases", "This study is looking at how a special type of radiation therapy, called NTS-WBRT (normal tissue sparing whole brain radiation therapy), affects the quality of life and symptoms for people with brain metastases (cancer that has spread to the brain). You would also receive Memantine, a standard medication. The researchers want to see if NTS-WBRT improves your quality of life and reduces your symptoms after 4 months. You might be able to join if you are at least 18 years old, have a solid tumor that has spread to the brain, and meet certain health criteria. About 41 people are expected to participate in this study, but its current recruitment status is unclear.", "design": "This is a Phase 2 interventional study, meaning all participants will receive the study treatments. It plans to enroll about 41 people.", "commitments": "The research study procedures include screening to see if you are eligible, receiving the study treatments, and attending evaluations and follow-up visits.", "compensation": "Not stated in the trial record.", "follow_up": "Your quality of life and symptom burden will be measured at 4 months after receiving NTS-WBRT.", }

Study design: Not specified.
What's involved: Not specified in the trial record.
Compensation: Not stated in the trial record.
Follow-up: Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NTS-WBRT in Brain Metastases

Recruiting

PHASE2Ages 18+InterventionalTreatment

Massachusetts General Hospital

~41 participants

Updated 2026-04-16 on ClinicalTrials.gov

What's tested:NTS-WBRT (normal tissue sparing whole brain radiation therapy)Memantine

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Change in Patient Reported Quality of Life for NTS-WBRT (normal tissue sparing whole brain radiation therapy)

Measured over 4 Months

+1 more outcome measured

Conditions

Brain Metastases

Where it's being run

1 sites across 1 states

Massachusetts1

Study leadership

Helen A Shih, MD, MS, MPH · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital

Who to contact

Helen A Shih, MD, MS, MPH

[email protected]

(617) 724-9627

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Any patient with a solid tumor diagnosis and any number of brain metastasis clinically indicated for cranial irradiation with whole brain radiation therapy

Age ≥ 18

Karnofsky Performance Status ≥ 70

Prior stereotactic radiosurgery (SRS) permissible per physician discretion

Prior craniotomy permissible per physician discretion. Protocol radiation therapy should be initiated ≥2 weeks after craniotomy.

Prior partial brain radiation therapy permissible if target volume \< 50% brain and per physician discretion

Expectant \> 6 months survival

Ability to understand and the willingness to sign a written informed consent document.

Fluency in English, able to complete questionnaires and neurocognitive testing

Ability to undergo MRI with gadolinium examination

Ability to return for follow-up examinations throughout the course of this study for a maximum of 2 years after radiation treatment completion

Any prior, concomitant, or post-radiotherapy systemic therapy is permitted at discretion of treating physicians

Negative pregnancy test for premenopausal women

Exclusion

Leptomeningeal disease (by any one or more of clinical assessment, radiographic assessment, or cerebrospinal fluid study)

Prior whole brain radiation therapy

Pre-existing or current use of memantine or other NMDA antagonists

Known allergy to contrast used in imaging studies and/or inability to have MRI imaging

Uncontrolled intercurrent illness that could significantly affect baseline cognitive function as determined by the enrolling clinician, such as symptomatic congestive heart failure, unstable angina pectoris, prior CVA, significant uncontrolled epilepsy or psychiatric illness/social situations that would limit compliance with study requirements

Pregnant or unwilling to use appropriate contraception to prevent pregnancy during the time of radiation therapy

Concurrent participation in an investigational systemic therapy protocol.

What this trial measures

Change in Patient Reported Quality of Life for NTS-WBRT (normal tissue sparing whole brain radiation therapy)4 Months
Assessed by Functional Assessment of Cancer Therapy-Brain (FACT-Br) questionnaire. Score range is 0-200 and the higher the score, the better the outcome.
Change in Patient Reported Symptom Burden for NTS-WBRT (normal tissue sparing whole brain radiation therapy)4 Months
Assessed by Functional Assessment of Cancer Therapy-Brain (FACT-Br) questionnaire. Score range is 0-200 and the higher the score, the better the outcome.

Trialytics